The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma (nccRCC): Safety and efficacy from CheckMate 920.
 
Scott S. Tykodi
Consulting or Advisory Role - Bristol-Myers Squibb; Intellisphere, LLC; Merck; Natera
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Clinigen Group (Inst); Exelixis (Inst); Genentech (Inst); Jounce Therapeutics (Inst); Merck Sharp & Dohme (Inst); Nektar (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending (Inst)
 
Lucio N. Gordan
Employment - Florida Medical Clinic
Leadership - Florida Cancer Specialists
Honoraria - Ameris Pharma
Consulting or Advisory Role - Janssen Oncology
Speakers' Bureau - Myriad Genetics
 
Robert S. Alter
Consulting or Advisory Role - Bayer; Eisai; EMD Serono; Janssen Biotech
Speakers' Bureau - Astellas Pharma; Bayer; Janssen Oncology; Pfizer
 
Edward Arrowsmith
Employment - Tennessee Oncology
Stock and Other Ownership Interests - OneOncology
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calistoga Pharmaceuticals (Inst); Celgene (Inst); Cephalon (Inst); Chorus (Inst); Clovis Oncology (Inst); Cougar Biotechnology (Inst); Eisai (Inst); EMD Serono (Inst); Evelo Biosciences (Inst); Exelixis (Inst); Genentech (Inst); Gilead Sciences (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Janssen Research & Development (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst); Modra Pharmaceuticals (Inst); Novartis (Inst); Oncogenex (Inst); Onyx (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Sarah Cannon Research Institute (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Flatiron Health; OneOncology; Sarah Cannon Research Institute
Other Relationship - Sarah Cannon Research Institute
 
Michael Roger Harrison
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Exelixis; Fujifilm; Genentech; Janssen Oncology; Pfizer
Speakers' Bureau - Exelixis; Genentech
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Exelixis (Inst); Genentech (Inst); Merck (Inst); Pfizer (Inst); Seagen (Inst)
 
Ivor John Percent
No Relationships to Disclose
 
Rakesh Singal
Consulting or Advisory Role - Dendreon
 
Peter J. Van Veldhuizen
Employment - HCA MIDWEST HEALTH
Honoraria - Sanofi
Research Funding - Multiple Clinical Trials
 
Daniel J. George
Leadership - Capio BioSciences
Honoraria - Acceleron Pharma; American Association for Cancer Research; Axess Oncology; Bayer; EMD Serono; Exelixis; Janssen Oncology; Millennium Medical Publishing; OncLive; Pfizer; Sanofi; UroToday
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Constellation Pharmaceuticals; Exelixis; Genentech; Innocrin Pharma; Janssen; Merck Sharp & Dohme; Michael J. Hennessy Associates; Myovant Sciences; Pfizer; Sanofi; Vizuri
Speakers' Bureau - Bayer; Exelixis; Sanofi
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Dendreon (Inst); Exelixis (Inst); Innocrin Pharma (Inst); Janssen Oncology (Inst); Novartis (Inst); Pfizer (Inst); Sanofi/Aventis (Inst)
Travel, Accommodations, Expenses - Bayer; Exelixis; Janssen Oncology; Merck; Pfizer; Sanofi; UroToday
 
Thomas E. Hutson
Employment - Texas Oncology
Honoraria - Astellas Pharma; Bayer/Onyx; Bristol-Myers Squibb; Eisai; Exelixis; Johnson & Johnson; Novartis; Pfizer
Consulting or Advisory Role - Astellas Pharma; Bayer/Onyx; Bristol-Myers Squibb; Eisai; Exelixis; Johnson & Johnson; Novartis; Pfizer
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; Eisai; Exelixis; Johnson & Johnson; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Johnson & Johnson (Inst); Pfizer (Inst)
 
Joshua Zhang
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Jesus Zoco
Employment - Syneos Health
Consulting or Advisory Role - Syneos Health
 
Jennifer L. Johansen
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Arash Rezazadeh Kalebasty
Stock and Other Ownership Interests - ECOM Medical
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; EMD Serono; Exelis; Genentech; Novartis; Pfizer
Speakers' Bureau - Amgen; Astellas Medivation; AstraZeneca; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Genentech/Roche; Janssen; Merck; Novartis; Pfizer; Sanofi; Seattle Genetics/Astellas
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bavarian Nordic (Inst); Bayer (Inst); BeyondSpring Pharmaceuticals (Inst); BioClin Therapeutics (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); Epizyme (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Janssen (Inst); MacroGenics (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Astellas Medivation; AstraZeneca; Bayer; Eisai; Exelixis; Genentech; Janssen; Novartis; Pfizer; Prometheus